Nvidia forges healthcare partnerships to advance AI-driven genomics, drug discovery and more

Given the number of specialty companies in the industry, solving healthcare challenges with AI requires an ecosystem approach. At the recent J.P. Morgan Healthcare Conference in San Francisco, Nvidia announced several new AI-centric partnerships with industry leaders to advance genomics, drug discovery, and advanced healthcare services.

In an analyst briefing, Kimberly Powell, vice president of healthcare at Nvidia, described the “AI revolution” in healthcare, enabling new product creation. “Instead of humans writing code, you now have LLMs (large language models). You introduce data, and the machine learns from that data. It builds models and then writes software that executes on a GPU. We call that the AI factory.”

Nvidia has been evangelizing the concept of the AI factory over the past several months. It was prominent in CEO Jensen Huang’s keynote at CES and at the National Retail Federation’s annual conference during a panel with Azita Martin, vice president and general manager of retail and CPG. The idea behind the AI factory is to shift computing to meet AI’s data-heavy demands. Powell explained how, with AI, data is the raw material, and tokens are the commodity, with the tokens being generated in the factory.